CN112641665A - 一种抗敏修复精华液及其制备方法 - Google Patents
一种抗敏修复精华液及其制备方法 Download PDFInfo
- Publication number
- CN112641665A CN112641665A CN201910976329.4A CN201910976329A CN112641665A CN 112641665 A CN112641665 A CN 112641665A CN 201910976329 A CN201910976329 A CN 201910976329A CN 112641665 A CN112641665 A CN 112641665A
- Authority
- CN
- China
- Prior art keywords
- extract
- content
- less
- allergy
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 34
- 230000008439 repair process Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 229940069445 licorice extract Drugs 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 7
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 7
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 6
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract 10
- 238000003756 stirring Methods 0.000 claims description 36
- 238000001816 cooling Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000002211 L-ascorbic acid Substances 0.000 claims 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 24
- 229960004106 citric acid Drugs 0.000 abstract description 12
- 229960001340 histamine Drugs 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 201000004624 Dermatitis Diseases 0.000 abstract description 8
- 229940074410 trehalose Drugs 0.000 abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- 230000007815 allergy Effects 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 244000063299 Bacillus subtilis Species 0.000 abstract description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract description 2
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 2
- 241000196324 Embryophyta Species 0.000 abstract 1
- 239000009429 Ginkgo biloba extract Substances 0.000 abstract 1
- 239000000043 antiallergic agent Substances 0.000 abstract 1
- 230000000249 desinfective effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 19
- 241001122767 Theaceae Species 0.000 description 18
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001523681 Dendrobium Species 0.000 description 2
- 241001076416 Dendrobium tosaense Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 102000003563 TRPV Human genes 0.000 description 2
- 108060008564 TRPV Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 229940051810 licorice root extract Drugs 0.000 description 2
- 235000020725 licorice root extract Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940092665 tea leaf extract Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及化妆品领域,具体涉及一种抗敏修复精华液及其制备方法。一种抗敏修复精华液,该组合物主要包括:左旋维生素C、茶叶提取物、柠檬酸、海藻糖、甘草酸二钾、甘草浸膏。茶叶提取物和银杏叶提取物的含量不同时为零。左旋维生素C含量不低于99.5%,寡肽‑1为三肽分子,序列是GHK,其中蛋白的含量不低于1.63mg/ml。该抗敏修复精华液中的甘草酸二钾为抗过敏剂,可以阻止皮肤中组胺的释放,具有解毒、消毒、抗过敏作用,长期使用无副作用。甘草浸膏中主要的有效成分为甘草甜素,在抗敏方面,可抑制皮肤炎症的产生,抑制皮肤上的金黄色葡萄球菌和枯草杆菌繁殖。并可以调节皮肤对外界刺激的免疫力。两者皆来源于天然植物,无副作用及毒性。
Description
技术领域
本发明涉及化妆品领域,具体涉及一种抗敏修复精华液及其制备方法
背景技术
相当一部分的皮肤过敏现象(红肿热痛痒)都属于炎症反应。当人体皮肤失去正常的屏障功能或当外界刺激超过人体皮肤屏障所能承受的最大限度时,容易引发皮肤炎症现象。其过程机理如下:
物理化学刺激/UV光照刺激--激活蛋白激酶--产生Ros氧自由基簇--NF-kB(核转录因子)传递刺激信号进入细胞核--DNA翻译信号,转化为指令进行蛋白合成。最终,细胞合成IL-1(白介素)、TNF-a(肿瘤坏死因子)、LTB4(白三烯)和PGE2(前列腺素)4种致炎因子使皮肤出现炎症。如果刺激原是过敏原,皮肤上的Mast cell(肥大细胞)将会释放组胺,刺激皮肤上的TRPV受体和Mrgpr受体等,产生痒觉。同时组胺也作为第一部分的刺激原,诱导炎症反应,发生风团和丘疹等。
化妆品抗敏的机理有:1.抑制致炎因子的合成。当皮肤细胞受到外界刺激,引发炎症反应时,通过抑制细胞内致炎因子的合成,可以减轻甚至消除皮肤炎症。2.抑制组胺释放及其与受体的结合。当皮肤受过敏源刺激时,会释放大量组胺,组胺有强烈的舒血管作用,并能使毛细血管和微静脉的管壁通透性增加,血浆漏入组织,导致局部组织水肿。并且组胺刺激皮肤上的TRPV受体和Mrgpr受体,产生痒觉。通过抑制组胺释放及其与受体的结合,可以起到抗敏的作用。3.降低细胞内钙离子浓度。当皮肤受到刺激时,刺激源和神经突触之间的信号传递需要钙离子。当钙离子的浓度受到抑制,则人体无法感受到刺激,因而不会出现生理反应。
抗敏产品一般通常会从不同的机理入手,多方面对皮肤起作用,从而达到更好的效果。本发明从抑制组胺释放和中和皮肤中自由基入手,选用茶叶提取物、甘草浸膏和甘草酸二钾来抑制皮肤组织组胺的释放,并配合维生素C中和皮肤中的自由基,减少皮肤因受到外界刺激发生炎症而产生的损伤而达到消炎修复的效果。目前市面上的抗敏产品中,含维C的产品并不多见。本发明中的产品含有高浓度的维C,有较好的清除自由基的作用,能阻挡因外界刺激,尤其是紫外线等的刺激产生的自由基。并且是皮肤中胶原蛋白再生所必须的物质。可以很好的与配方中其他的抗敏成分形成互补,特别是对晒后皮肤发炎有较好的修复作用。
发明内容
本发明综合考虑了多种抗敏机理,本发明的一个目的是提出一种抗敏修复精华液,该精华液通过将维生素C、茶叶提取物、柠檬酸、海藻糖、甘草酸二钾、甘草浸膏和丁二醇进行复配,通过茶叶提取物抑制组胺的释放,甘草浸膏和甘草酸二钾抑制炎症因子的合成,达到抗敏效果。
本发明的另一个目的是提出上述抗敏修复精华液的制备方法。
为了实现上述的第一个目的,本发明采用了以下设计方案:
一种抗敏修复精华液,该组合物按百分质量比计包括以下的组分:
上面所述左旋维生素C含量不低于99.5%。茶叶提取物中茶多酚含量不低于98%。甘草浸膏抽提物为黑色块状固体,其中甘草甜素含量在15%以上,干燥失重在35%以下。铁皮石斛提取液中石斛多糖含量不小于20%;茶树花SOD其SOD活性不小于1512U/g。海藻糖为白色结晶粉末,其含量不低于99%,柠檬酸为白色结晶粉末,含量不低于99%。
作为优选,该组合物按质量百分比计包括以下的组分:
作为优选,该组合物按质量百分比计包括以下的组分:
作为在优选所述的左旋维生素C是葡萄糖经两段发酵法得到的白色粉末,其含量大于99%。
作为优选所述的20%铁皮石斛提取液具有抗炎修复、止痒舒敏、抗衰老、抗辐射,起到抗炎、抗病毒、活化自身皮肤细胞,提高免疫力之功效,石斛多糖含量达到不少于20%。
作为优选所述的茶树花SOD浸膏为白色膏体,其SOD活性不小于1512U/g。
作为优选所述的海藻糖是以玉米为原料,采用发酵酶解二次结晶法制得,其含量大于99%。
作为优选所述的茶叶提取物,其中茶多酚含量不小于98%。
作为优选所述的甘草浸膏抽提物为黑色块状固体,其中甘草甜素含量在15%以上,干燥失重在35%以下。
作为优选所述的柠檬酸是发酵制得的白色结晶性粉末,其中一水柠檬酸的含量大于99.5%。
上述抗敏修复精华液中,还可以包含防腐剂0.35%~0.5%。
为了实现上述的第二个目的,本发明采用了以下技术方案:
一种制备上述抗敏修复精华液的方法,该方法包括以下步骤:
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
维生素C是一种强还原剂,具有抗氧化作用。可以清除皮肤由于外界刺激及人体自身而产生的自由基。除此之外,它还可以促进皮肤胶原蛋白合成以及修复紫外线对皮肤造成的损害。
甘草浸膏中主要的有效成分为甘草甜素,在抗敏方面,可以抑制皮肤炎症的产生,抑制皮肤上的金黄色葡萄球菌和枯草杆菌繁殖。并可以调节皮肤对外界刺激的免疫力。
茶叶提取物对皮肤炎症有较好的抑制效果,可抑制皮肤中组胺的释放,并可以明显抑制透明质酸酶的活性。
附图说明
图1受试者胳膊部位图像示例
具体实施方式
本发明提供的抗敏修复精华液是以左旋维生素C、甘草浸膏、茶树花SOD、茶叶提取物、海藻糖、柠檬酸为主要成分,辅以化妆品常用基质成分保湿剂、增稠剂、防腐剂及水制成。下面列举一部分具体实施例对本发明进行说明,但并不限制本发明的内容。
实施例1
抗敏修复精华液:
组成上述抗敏修复精华液的组分及其百分数含量为:
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
实施例2
抗敏修复精华液:
组成上述抗敏修复精华液的组分及其百分数含量为:
左旋维生素C | 10 |
海藻糖 | 2 |
甘草浸膏 | 0.25 |
茶树花SOD | 0.15 |
茶叶提取物 | 0.1 |
柠檬酸 | 1.5 |
黄原胶 | 0.1 |
EDTA-2Na | 0.05 |
丁二醇 | 5 |
乙氧基二甘醇 | 25 |
防腐剂 | 适量 |
去离子水 | 余量 |
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
实施例3
抗敏修复精华液:
组成上述抗敏修复精华液的组分及其百分数含量为:
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
实施例4
抗敏修复精华液:
组成上述抗敏修复精华液的组分及其百分数含量为:
左旋维生素C | 5 |
海藻糖 | 2 |
甘草浸膏 | 0.1 |
茶树花SOD | 0.2 |
茶叶提取物 | 0.5 |
柠檬酸 | 0.25 |
黄原胶 | 0.3 |
EDTA-2Na | 0.05 |
丁二醇 | 5 |
乙氧基二甘醇 | 25 |
防腐剂 | 适量 |
去离子水 | 余量 |
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
实施例3效果评价
本实验选择实施例3中提供的抗敏修复精华液进行临床实验
选择90名来自不同城市的志愿者进行抗敏修复功效测试。随机分成3组,每组人员分别在左手臂内侧选择2个2cm×2cm的区域,进行斑贴实验,分别对测试区域标记。对不同区域进行相同致敏处理,涂抹含量为5%的辣椒碱,涂抹均匀,待10-15分钟涂抹区域出现发痒刺痛红肿现象。进行抗敏修复测试,分别以纯水为空白对照、同类产品做阳性对照,分别对过敏区域进行涂抹,涂抹量为泵头瓶按压1-2次,测试时长2h。数据采集:分别在0min、30min、60min、60min以上进行拍照取证及感官表述。记录实验过程中红肿发痒变化情况。抗敏修复测试情况:
从上述表格和图1可以看出,该抗敏修复产品具有良好的缓解过敏症状,镇定肌肤,消红去肿的修复效果,且效果市场上同类产品更好。
综上所述内容可知:该抗敏修复精华液具有显著的快速镇定、消肿、缓解过敏症状的功效,且效果有优于市面所售产品。
Claims (9)
4.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的左旋维生素C 是葡萄糖经两段发酵法得到的白色粉末,其含量大于99%。
5.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的茶叶提取物中茶多酚的含量不低于98%。
6.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的甘草浸膏抽提物为黑色块状固体,其中甘草甜素含量在15%以上,干燥失重在35%以下。
7.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的甘草酸二钾,为白色粉末,其中有效物质含量不小于98%。
8.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的海藻糖为以玉米为原料,经过发酵酶解二次结晶法制得,其含量不低于99%。
9.根据权利要求1或2或3所述的一种保湿促循环精华液,其特征在于所述的茶树花SOD浸膏为白色膏体,其SOD活性不小于1512U/g。
一种制备权利要求1~11任意一项权利要求所述的保湿促循环精华液的方法。其特征在于该方法包括以下步骤:
1)将去离子水和EDTA-2Na加入反应锅中,开启搅拌,加热至75℃-80℃。
2)将茶叶提取物加入到丁二醇和乙氧基二甘醇的混合液中,在常温下搅拌,直至溶解为褐色透明液体。
3)开冷却循环水,搅拌降温,待温度降至45℃-50℃时,将上述第二步中所述混合物加入反应锅中,再加入黄原胶、茶树花SOD、甘草浸膏、柠檬酸和海藻糖,搅拌溶解完全。
4)继续搅拌冷却至40℃以下,加入左旋维生素C,至溶解完全。
5)停止搅拌,结束。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910976329.4A CN112641665A (zh) | 2019-10-10 | 2019-10-10 | 一种抗敏修复精华液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910976329.4A CN112641665A (zh) | 2019-10-10 | 2019-10-10 | 一种抗敏修复精华液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112641665A true CN112641665A (zh) | 2021-04-13 |
Family
ID=75343168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910976329.4A Pending CN112641665A (zh) | 2019-10-10 | 2019-10-10 | 一种抗敏修复精华液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112641665A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846514A (zh) * | 2012-09-12 | 2013-01-02 | 杭州小青生物科技有限公司 | 一种用于晒后修复的含茶多酚的水性凝胶及其制备方法 |
CN104814919A (zh) * | 2015-05-13 | 2015-08-05 | 朱敏 | 一种保湿祛皱面膜液、制造方法及保湿祛皱面膜 |
CN104814921A (zh) * | 2015-05-13 | 2015-08-05 | 朱敏 | 一种祛痘淡痕面膜液、制造方法及祛痘淡痕面膜 |
CN106265340A (zh) * | 2016-09-18 | 2017-01-04 | 中华全国供销合作总社南京野生植物综合利用研究所 | 一种含茶树花花蕊的全天然爽身粉 |
CN107184486A (zh) * | 2017-07-06 | 2017-09-22 | 曾万祥 | 一种面膜液及含有该面膜液的面膜 |
CN108635275A (zh) * | 2018-07-27 | 2018-10-12 | 北京化工大学 | 一种抗氧化组合物及其在精华液中的应用 |
CN108653013A (zh) * | 2018-06-28 | 2018-10-16 | 芜湖扬展新材料科技服务有限公司 | 一种植物保湿水润晒后修复霜及其制备方法 |
CN109431841A (zh) * | 2018-12-25 | 2019-03-08 | 樊利平 | 一种抗氧化抗衰老的美白精华液及其制备方法 |
CN110037973A (zh) * | 2019-05-28 | 2019-07-23 | 南靖珠曼生物科技有限公司 | 一种赋活精华液及其制备方法 |
-
2019
- 2019-10-10 CN CN201910976329.4A patent/CN112641665A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846514A (zh) * | 2012-09-12 | 2013-01-02 | 杭州小青生物科技有限公司 | 一种用于晒后修复的含茶多酚的水性凝胶及其制备方法 |
CN104814919A (zh) * | 2015-05-13 | 2015-08-05 | 朱敏 | 一种保湿祛皱面膜液、制造方法及保湿祛皱面膜 |
CN104814921A (zh) * | 2015-05-13 | 2015-08-05 | 朱敏 | 一种祛痘淡痕面膜液、制造方法及祛痘淡痕面膜 |
CN106265340A (zh) * | 2016-09-18 | 2017-01-04 | 中华全国供销合作总社南京野生植物综合利用研究所 | 一种含茶树花花蕊的全天然爽身粉 |
CN107184486A (zh) * | 2017-07-06 | 2017-09-22 | 曾万祥 | 一种面膜液及含有该面膜液的面膜 |
CN108653013A (zh) * | 2018-06-28 | 2018-10-16 | 芜湖扬展新材料科技服务有限公司 | 一种植物保湿水润晒后修复霜及其制备方法 |
CN108635275A (zh) * | 2018-07-27 | 2018-10-12 | 北京化工大学 | 一种抗氧化组合物及其在精华液中的应用 |
CN109431841A (zh) * | 2018-12-25 | 2019-03-08 | 樊利平 | 一种抗氧化抗衰老的美白精华液及其制备方法 |
CN110037973A (zh) * | 2019-05-28 | 2019-07-23 | 南靖珠曼生物科技有限公司 | 一种赋活精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109939058B (zh) | 一种防蓝光的化妆品组合物及其制备方法 | |
CN111214429B (zh) | 修护精华及其制备方法 | |
CN105030621A (zh) | 一种保湿祛痘爽肤水及其制备方法 | |
CN111228207B (zh) | 祛湿疹护臀霜及其制备方法 | |
CN113018238A (zh) | 一种抑菌消炎清爽益肤的祛痘凝胶及其制备方法 | |
CN105106049B (zh) | 一种用于眼部护理的组合物及制备方法 | |
KR101752232B1 (ko) | 탈모방지 및 발모촉진용 조성물의 제조방법 | |
KR101142541B1 (ko) | 효소처리를 이용한 혼합생약재 추출물을 함유하는 피부 주름개선용 화장료 조성물 및 그 추출방법 | |
CN109303724A (zh) | 一种新型含艾叶的舒缓修护原液组合物 | |
KR100795993B1 (ko) | 아토피성 피부용 화장료 조성물 | |
CN110559230A (zh) | 一种抗衰除皱精华水及其制备方法 | |
CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
CN108938511B (zh) | 天然植物提取物的组合物及在皮肤保湿祛痘产品中的应用 | |
CN108078868B (zh) | 一种用于护肤品的抗过敏组合物 | |
CN110787119A (zh) | 一种抗菌护肤中药组合物及其制备方法和应用 | |
CN112641665A (zh) | 一种抗敏修复精华液及其制备方法 | |
CN109276514A (zh) | 一种新型舒缓修护面膜及其制备方法 | |
CN109010572A (zh) | 一种具有防晒增效及抗衰老作用的中药组合物及其制备方法和应用 | |
CN111202821B (zh) | 具有舒敏抗炎功效的中药提取物及其制备方法与应用 | |
KR20180138245A (ko) | 생약 추출물을 포함하는 화장료 또는 약학 조성물 및 그의 제조방법 | |
CN109431824B (zh) | 一种抗菌除臭凝胶及其应用 | |
CN107970286B (zh) | 一种治疗肾虚型牙齿松浮脱落的中药喷雾及其制备方法 | |
CN107362113B (zh) | 一种中药组合物及其制备方法和应用 | |
CN111346173A (zh) | 中药组合物、中药精油、中药护肤品和制备方法 | |
KR100552307B1 (ko) | 항노화 효과가 있는 한약제 추출물이 첨가된 화장료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |